Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
Manganiello
Vincent
V
Section on Biochemical Physiology, Pulmonary-Critical Care Medical Branch, National Heart, Lung, and Blood Institute/NIH/DHHS, Building 10, Room 5N307, 9000 Rockville Pike, Bethesda, MD. manganiv@nhlbi.nih.gov
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000818:Animals; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006801:Humans; D009712:Nucleotides, Cyclic / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
D009712:Nucleotides, Cyclic; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human; D006152:Cyclic GMP